Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: J Neurooncol

Search In Journal Title:

Abbravation: Journal of Neuro-Oncology

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1007/bf03194509

Search In DOI:

ISSN

1573-7373

Search In ISSN:
Search In Title Of Papers:

Combination of 6thioguanine capecitabine and ce

Authors: Tobias Walbert Mark R Gilbert Morris D Groves Vinay K Puduvalli W K Alfred Yung Charles A Conrad George C Bobustuc Howard Colman Sigmund H Hsu B Nebiyou Bekele Wei Qiao Victor A Levin
Publish Date: 2010/07/23
Volume: 102, Issue: 2, Pages: 273-280
PDF Link

Abstract

We evaluated the efficacy of temozolomide TMZ or lomustine CCNU in combination with 6thioguanine capecitabine and celecoxib for the treatment of recurrent highgrade glioma Fortythree patients with recurrent glioblastoma and 31 patients with recurrent anaplastic glioma AG were enrolled in this openlabel noncomparative study Patients previously treated with TMZ received CCNU while all others received TMZ all patients received 6thioguanine capecitabine and celecoxib Endpoints were 12month progressionfree survival PFS for patients with AG 6month PFS for patients with glioblastoma duration of PFS and MRIbased objective response rates Results from the TMZ and CCNU treatment arms were combined in the final analysis because there was no statistically significant difference between them Thirtyeight patients with glioblastoma were treated with the lomustinebased regimen and five received the TMZbased regimen For the 43 glioblastoma patients the objective response rate was 12 and 33 had stable disease the 6month PFS was 14 and median overall survival 32 weeks For the 31 AG patients the combined objective response rate was 26 and 42 had stable disease the 12 month PFS was 44 Treatment was reasonably well tolerated with hematological toxicity common and more frequent with CCNU than TMZ The combination therapy with 6thioguanine capecitabine and celecoxib plus CCNU or TMZ does not appear to be more effective than other alkylating agent schedules for patients with recurrent glioblastoma The combination however is promising for patients with recurrent highgrade AG

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma
  2. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells
  3. Origins and clinical implications of the brain tumor stem cell hypothesis
  4. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design
  5. All- trans retinoic acid inhibits craniopharyngioma cell growth: study on an explant cell model
  6. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
  7. Quality of radiosurgery for single brain metastases with respect to treatment technology: a matched-pair analysis
  8. Phase II trial of temozolomide in children with recurrent high-grade glioma
  9. Management of patients with recurrence of diffuse low grade glioma
  10. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms
  11. Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery
  12. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types
  13. Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma
  14. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
  15. A new prognostic scoring scale for patients with primary WHO grade III gliomas based on molecular predictors
  16. Extraneural metastatic medulloblastoma in an adult
  17. Incidence of craniopharyngioma in Denmark ( n = 189) and estimated world incidence of craniopharyngioma in children and adults
  18. Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery
  19. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades
  20. Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas
  21. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma
  22. Multiple paraneoplastic diseases occurring in the same patient after thymomectomy
  23. Age alone is not a predictor for survival in glioblastoma
  24. Clear cell Meningioma, an uncommon variant of meningioma: a clinicopathologic study of nine cases
  25. Weight of epilepsy in brain tumor patients
  26. Effects of sequential chemotherapy of FOLFIRI/FOLFOX on the endocrine axes of ACTH–cortisol and renin–angiotensin–aldosterone
  27. PI3Kinase signaling in glioblastoma
  28. Gamma Knife radiosurgery for brainstem metastases: the UCSF experience
  29. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma
  30. Health related quality of life and cognitive status in patients with glioblastoma multiforme receiving escalating doses of conformal three dimensional radiation on RTOG 98-03
  31. Role of platelet derived growth factor receptor (PDGFR) over-expression and angiogenesis in ependymoma
  32. Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults
  33. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells
  34. Convection enhanced delivery of boronated EGF as a molecular targeting agent for neutron capture therapy of brain tumors
  35. Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma
  36. Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery
  37. Variation of O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma
  38. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma
  39. Rho GTPases in primary brain tumor malignancy and invasion
  40. Limited detection of IgH gene rearrangements in plasma of patients with primary central nervous system lymphoma
  41. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of ‘hook effect’
  42. Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma
  43. Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease
  44. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
  45. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme
  46. Elevation of osteopontin levels in brain tumor cells reduces burden and promotes survival through the inhibition of cell dispersal
  47. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors
  48. Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas
  49. Evaluation of fluoride-labeled boronophenylalanine-PET imaging for the study of radiation effects in patients with glioblastomas
  50. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics
  51. The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma
  52. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen
  53. Images in neuro oncology: Primary extraaxial cerebellopontine angle ependymoma
  54. The peabody picture vocabulary test as a pre-screening tool for global cognitive functioning in childhood brain tumor survivors
  55. Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma
  56. Skull base meningiomas: neurological outcome after microsurgical resection
  57. Stereotactic biopsy of brainstem lesions: 21 years experiences of a single center
  58. Caloric restriction reduces edema and prolongs survival in a mouse glioma model
  59. Algorithmic three-dimensional analysis of tumor shape in MRI improves prognosis of survival in glioblastoma: a multi-institutional study
  60. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors
  61. The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis
Search Result: